Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Cyclophilin D in Mitochondrial Dysfunction: a Key Player in Neurodegeneration?

Version 1 : Received: 6 July 2023 / Approved: 7 July 2023 / Online: 7 July 2023 (11:06:01 CEST)

A peer-reviewed article of this Preprint also exists.

Coluccino, G.; Muraca, V.P.; Corazza, A.; Lippe, G. Cyclophilin D in Mitochondrial Dysfunction: A Key Player in Neurodegeneration? Biomolecules 2023, 13, 1265. Coluccino, G.; Muraca, V.P.; Corazza, A.; Lippe, G. Cyclophilin D in Mitochondrial Dysfunction: A Key Player in Neurodegeneration? Biomolecules 2023, 13, 1265.

Abstract

Mitochondrial dysfunction plays a pivotal role in numerous complex diseases. Understanding the molecular mechanisms by which the “powerhouse of the cell” turns into the “factory of death” is an exciting yet challenging task that can unveil new therapeutic targets. The mitochondrial matrix protein CyPD is a peptidylprolyl cis-trans isomerase involved in the regulation of the permeability transition pore (mPTP). The mPTP is a multi-conductance channel in the inner mitochondrial membrane whose dysregulated opening can ultimately lead to cell death and whose involvement in pathology has been extensively documented over the past few decades. Moreover, several mPTP-independent CyPD interactions have been identified, indicating that CyPD could be involved in the fine regulation of several biochemical pathways. To further enrich the picture, CyPD undergoes several post-translational modifications that regulate both its activity and interaction to its clients. Here, we will dissect what is currently known about CyPD and critically review the most recent literature about its involvement in neurodegenerative disorders, focusing on Alzheimer’s Disease and Parkinson’s Disease, supporting the notion that CyPD could serve as a promising therapeutic target for the treatment of such conditions. Notably, significant efforts have been made to develop CyPD-specific inhibitors, which hold promise for the treatment of such complex disorders.

Keywords

Cyclophilin D (CyPD); mitochondrial permeability transition (mPTP); Alzheimer’s Disease (AD); Parkinson’s Disease (PD); mitochondria; neurodegeneration

Subject

Biology and Life Sciences, Aging

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.